Investment Thesis
Ocean Biomedical exhibits extreme financial distress with negative stockholders' equity of -$92.4M, liabilities exceeding assets by 59x, and a liquidity crisis evidenced by a 0.06x current ratio against $800K in cash. The negative revenue of -$2.0M and operating cash burn of -$356.0K indicate either severe product returns/accounting issues or pre-revenue status incompatible with $94M in liabilities, creating an existential solvency risk with minimal cash runway.
Strengths
- Operates in pharmaceutical sector with inherent high-margin potential
- Maintains $800K in cash providing short-term runway
- Potential turnaround opportunity if viable pipeline assets exist
Risks
- Negative stockholders' equity indicating technical insolvency
- Negative revenue of -$2.0M suggesting major product returns or accounting irregularities
- Liquidity crisis with current ratio of 0.06x and liabilities $94M vs assets $1.6M
- Operating cash burn of -$356.0K with only $800K cash (2.2 month runway)
- No insider Form 4 filings in 90 days indicating lack of management confidence
- Severe accumulated losses of -$8.2M in latest period
Key Metrics to Watch
- Quarterly cash balance and burn rate trend
- Revenue sign and trajectory (confirm if negative revenues persist)
- Debt restructuring announcements or refinancing activities
- Clinical trial progress or regulatory approvals if in pipeline stage
- Insider buying activity and management changes
Financial Metrics
Revenue
-2.0M
Net Income
-8.2M
EPS (Diluted)
$-0.09
Free Cash Flow
-356.0K
Total Assets
1.6M
Cash
800.0K
Profitability Ratios
Gross Margin
N/A
Operating Margin
46.8%
Net Margin
402.7%
ROE
N/A
ROA
-520.9%
FCF Margin
17.4%
Balance Sheet & Liquidity
Current Ratio
0.06x
Quick Ratio
0.06x
Debt/Equity
N/A
Debt/Assets
5,940.6%
Interest Coverage
-3.19x
Long-term Debt
N/A
Disclaimer: This analysis is generated by AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: 2026-04-13T12:18:21.546854 |
Data as of: 2025-03-31 |
Powered by Claude AI